Does semaglutide cause pancreatitis?

Current evidence does not establish a direct causal link. Acute pancreatitis remains a labeled warning because cases have been reported, but randomized data have not shown an excess against placebo or active comparators. The event is rare, and many trials excluded people with recent or chronic pancreatitis, so individual risk factors still matter.

What are pancreatitis warning symptoms while using semaglutide?

The key pattern is persistent or severe upper-abdominal pain that may radiate to the back, with or without nausea or vomiting. That is different from brief fullness or mild nausea. The pattern warrants prompt medical assessment because symptoms alone cannot distinguish pancreatitis from gallbladder disease or other abdominal conditions.

Can someone with a history of pancreatitis use semaglutide?

It requires an individualized prescriber decision. Earlier Wegovy labeling emphasized that people with prior pancreatitis had not been studied, and many pivotal trials excluded that history. SELECT included 69 people whose acute episode was more than 180 days earlier; none had a confirmed recurrence, but that group was too small to answer the question for everyone.

How are gallstones connected to semaglutide and pancreatitis?

Gallstones provide a plausible indirect pathway. Semaglutide and substantial weight reduction have been associated with more gallbladder events. If a stone moves into the shared drainage area for the bile and pancreatic ducts, it can trigger acute pancreatitis. In STEP 1, two of the three semaglutide participants with pancreatitis also had gallstones.

What does a prescriber check before prescribing semaglutide?

The review commonly covers previous acute or chronic pancreatitis, gallstones and gallbladder procedures, alcohol intake, triglyceride levels, tobacco use and medications linked with pancreatic inflammation. These factors do not all lead to the same decision. They help the prescriber judge whether semaglutide fits the person's complete clinical picture.

Semaglutide and Pancreatitis: What Studies Show

Semaglutide and pancreatitis have a warning-label relationship, but randomized trials have not shown an excess of acute pancreatitis against placebo or active comparators. That is not the same as proving zero risk. The event is rare, the pivotal trials often excluded people with recent or chronic pancreatitis, and postmarketing reports continue to be monitored.

The practical answer is two-part: know the specific pain pattern that needs prompt assessment, and make sure the prescriber knows about prior pancreatitis, gallstones, alcohol use, high triglycerides, tobacco use and relevant medications before treatment begins.

What the semaglutide and pancreatitis warning means

The January 2026 Wegovy prescribing information says acute pancreatitis, including hemorrhagic or necrotizing cases, has been observed with GLP-1 receptor agonists. It directs clinicians to stop Wegovy and begin appropriate management when pancreatitis is suspected. A warning records a serious potential event and sets a response; it does not by itself establish how much of the risk came from the drug rather than a patient's other risk factors.

History needs careful wording. The 2022 Wegovy label explicitly said the medicine had not been studied in people with a history of pancreatitis. That limitation is absent from the current label, but the evidence gap has not vanished: many SUSTAIN and PIONEER trials excluded any history, while STEP 1 excluded chronic pancreatitis and acute pancreatitis within the prior 180 days. A prior episode therefore remains an individualized prescribing question, not a universal yes or no.

What the randomized trials found

The numbers are small enough that absolute counts matter more than a broad reassurance. In STEP 1, 1,961 adults with overweight or obesity were randomized for 68 weeks. Wilding and colleagues reported in the New England Journal of Medicine in 2021 that three of 1,306 semaglutide participants had adjudicated acute pancreatitis, or 0.2%, versus none of 655 placebo participants. Two of those three cases occurred with gallstones; all three were mild and resolved.

A 2023 pooled analysis of the diabetes trials gives a wider view. Across the SUSTAIN phase 3a program, adjudicated acute pancreatitis occurred in 7 of 3,150 people receiving injectable semaglutide, or 0.3%, and 3 of 1,657 receiving placebo or an active comparator, or 0.2%. The authors described the proportions as similar; these trials also largely screened out prior pancreatitis.

SELECT supplied longer and larger randomized evidence. In its 2025 prespecified safety analysis, acute pancreatitis occurred in 17 of 8,803 semaglutide participants, or 0.2%, and 24 of 8,801 placebo participants, or 0.3%. The difference was not statistically significant. None of the 69 participants with an acute episode more than 180 days before screening had a confirmed recurrence, but 69 people are too few to settle risk for everyone with that history.

Why observational studies disagree

Claims databases include people who would not enter a trial, but they also inherit differences between who receives each drug. A 2023 JAMA cohort included 613 semaglutide users, 4,144 liraglutide users and 654 bupropion-naltrexone users without diabetes. There were only two pancreatitis events in the semaglutide group and one in the comparison group. The adjusted hazard ratio was 9.09 for the two GLP-1 drugs combined, but its 95% confidence interval ran from 1.25 to 66.00. That wide range and the combined-drug estimate make it a signal, not a semaglutide-specific risk measurement.

A much larger 2025 Diabetes Care analysis used three U.S. claims databases and more than 1.2 million people in each comparison. GLP-1 receptor agonists had a similar acute-pancreatitis rate to SGLT2 inhibitors: hazard ratio 1.01, with a 95% confidence interval of 0.90 to 1.13. Biliary disease was modestly higher, at 1.15, equivalent to fewer than one additional event per 1,000 person-years. This was class-level evidence in type 2 diabetes, not a semaglutide-only randomized comparison.

Tirzepatide is a related incretin medicine, not a way around the screening question. Its December 2025 Mounjaro label also carries an acute-pancreatitis warning and the stop-if-suspected instruction. A prescriber weighs the drugs' distinct profiles rather than treating a switch as an automatic workaround.

The gallstone pathway matters

Semaglutide is associated with more gallbladder events, particularly gallstones. In SELECT, gallbladder-related disorders occurred in 2.8% on semaglutide and 2.3% on placebo even though pancreatitis itself did not show an excess. Substantial or rapid weight loss can raise the likelihood of gallstones. A stone that moves into and blocks the shared drainage area for the bile and pancreatic ducts can trigger acute pancreatitis.

That indirect route helps explain why a prescriber asks about gallstones and the pace of weight change. It also explains why ordinary nausea is not enough to identify pancreatitis. The broader semaglutide safety review and guide to common semaglutide side effects put more common symptoms in context.

Symptoms that need prompt attention

The defining warning pattern is persistent or severe pain in the upper abdomen, sometimes radiating through to the back, with or without nausea or vomiting. It may feel steady rather than like brief cramping. This pattern warrants prompt medical assessment, especially when it is intense or does not ease.

Diagnosis cannot be made from symptoms alone. Clinicians use the history, examination, pancreatic enzymes and sometimes imaging to distinguish pancreatitis from gallbladder disease, reflux and the much more common gastrointestinal effects of a GLP-1 medicine.

What a prescriber screens for

The review typically covers prior acute or chronic pancreatitis, gallstones or gallbladder procedures, alcohol intake, triglyceride levels, tobacco use and medications associated with pancreatic inflammation. A 2025 case-control study of 2,245 adults who started a GLP-1 medicine for obesity found that prior gallstone disease was associated with 2.9 times the odds and prior pancreatitis with 4.8 times the odds of a later episode. It identified risk factors among users; it did not compare treatment with no treatment or isolate semaglutide.

Semaglutide through Promise is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe a compounded formulation after an individualized review; that decision is between the patient and the provider. Compounded semaglutide explains what that distinction means.

At Promise, a licensed provider reviews every request, and not everyone qualifies. The point of disclosing a previous episode or a gallstone history is not to produce an automatic rejection. It is to let the clinician judge the risk with the full record in view.